In its response to the statement of objections, Merck expressed a different understanding and confirmed that for its part, it always rejected the proposals from Rhône-Poulenc/Aventis to cease its production and purchase methylglucamine from Aventis. Merck's most important client, [customer 1] AG, was generally not prepared to accept methylglucamine of Aventis quality. Finally, due to Merck's expertise in producing speciality chemicals, Merck could produce methylglucamine at a relatively low cost, so it would not make sense for Merck to cease its production(30).
Recital 52, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002